H.R.3520 - Scheduling Tianeptine and Analogues Now to Defend Against Emerging Opioids Act; STAND Against Emerging Opioids Act (119th Congress)
Summary
H.R.3520, also known as the "Scheduling Tianeptine and Analogues Now to Defend Against Emerging Opioids Act" or the "STAND Against Emerging Opioids Act," aims to amend the Controlled Substances Act. The bill proposes to classify tianeptine, including its analogues, salts, isomers, and salts of isomers, as a Schedule III substance. This legislative action was introduced in the House of Representatives on May 20, 2025, and referred to the Committees on Energy and Commerce and the Judiciary.
Expected Effects
The primary effect of this bill, if enacted, would be to place tighter controls on the production, distribution, and use of tianeptine. This would likely reduce its availability and potentially decrease its abuse as an emerging opioid alternative. The scheduling would become effective 90 days after the enactment of the Act.
Potential Benefits
- Reduced potential for abuse and addiction related to tianeptine.
- Enhanced public safety through stricter regulation of a potentially harmful substance.
- Improved public health outcomes by limiting access to a substance with uncertain medical benefits and potential risks.
- Provides law enforcement with clearer guidelines and tools to address the illegal distribution and sale of tianeptine.
- May reduce healthcare costs associated with treating tianeptine abuse and addiction.
Potential Disadvantages
- May limit access to tianeptine for legitimate research purposes, if any exist.
- Could potentially drive users of tianeptine to seek other, possibly more dangerous, alternatives.
- May require additional resources for law enforcement and regulatory agencies to enforce the new scheduling.
- Could face opposition from individuals or groups who believe tianeptine has legitimate uses and should not be restricted.
- Potential for a black market to develop for tianeptine, increasing the risk of unregulated and potentially dangerous products.
Constitutional Alignment
The bill appears to align with the US Constitution, specifically with the powers granted to Congress under Article I, Section 8, to regulate interstate commerce and provide for the general welfare. The regulation of substances that pose a risk to public health and safety falls within the scope of these powers. There are no apparent infringements on individual liberties or rights as the bill aims to regulate a substance rather than restrict fundamental freedoms.
Impact Assessment: Things You Care About ⓘ
This action has been evaluated across 19 key areas that matter to you. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).